Latest Industry Insights

This article discusses the importance of data lineage and traceability for academic labs looking to maximize their publishing potential.

This article walks through the fundamentals of CRISPR screening and its most exciting applications, including unpicking cellular signaling networks, discovering how viruses like COVID-19 infect our cells and finding new drug targets.

In this interview with Anthony Schmitt PhD, senior vice president of science at Arima Genomics, we discover some of the advantages and applications of 3D genomics for fields such as cancer research and drug discovery.

In this interview, we hear from Dr. Eliza Small about the current challenges facing RNA therapeutic development and how these challenges can be overcome.

Technology Networks sat down with 2022 Illumina Agricultural Greater Good Initiative Grant winner Dr. Ranjana Bhattacharjee to learn more about her plans to use genomic analysis to improve the productivity and sustainability of yam crops.

Only 10 years ago, Nobel prize-winning work introduced CRISPR as a new and powerful genome editing tool. Here, three noteworthy applications of the technology are highlighted.

Technology Networks recently had the pleasure of speaking with Mark Fidock, vice president for Diagnostic Development, Precision Medicine at AstraZeneca, to find out how the company is “rising to the challenge” of delivering precision medicines for chronic diseases.

The biotech/genetic engineering company Colossal – co-founded in 2021 by renowned geneticist Professor George Church and serial entrepreneur Ben Lamm – announced it has begun a de-extinction project of the thylacine – an Australian marsupial commonly referred to as the “Tasmanian tiger”. Technology Networks interviewed the team to learn more.

Technology Networks recently had the pleasure of speaking to Dr. Philip Empey, to learn more about the Pharmacogenomics Center for Excellence and how it is working to prove the clinical utility of predictive PGx testing.

Technology Networks spoke to Dr. Cenk Sumen, chief scientific officer of MaxCyte, about their pioneering cell engineering platform.